オーラルセッション
- 第3日 5月17日（金） 10:50～11:10 C会場（101）
-
3C-O1-1050 PDF
プロテオミクスを駆使したがん最適医療への挑戦
Mass spectrometry-based proteomics is an indispensable tool for molecular, cellular biology and for the emerging field of clinical medicine. Especially, phosphoproteome is one of key signatures to understand the mode of action and mechanism of drug resistance of kinase inhibitors at the molecular level, pathway level and system level. Recently, we have developed a key technology on peptide separation for rapid and sensitive phosphoproteome analysis. We also developed a sensitive method to identify phospho tyrosine proteome using an immune affinity enrichment method.
We performed large-scale phosphoproteome analysis of colorectal cancer cell lines treated with Cetuximab, colorectal cancer patient-derived cells and organoids.We found kinase activity prediction by kinase substrate enrichment analysis (KSEA) was useful to extract activated kinases or signals in drug-resistant cells. However, KSEA depends on the kinase substrate relationship data, which are biased on well-characterized kinases. I will present our data and would like to discuss how we can overcome these challenges for the comprehensive detection of the markers for drug-efficacy and the target candidates for overcoming drug resistance.